Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 6 and maximally 15 years of age~* Diagnosis of asthma and baseline lung function tests as determined by the protocol~* Has required and received treatment with inhaled corticosteroids within the timeframe and doses specified in the protocol~Exclusion Criteria:~* Severe asthma~* Has required treatment with any non-inhaled corticosteroids within previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): budesonide/formoterol
- 2 (Type: ACTIVE_COMPARATOR): budesonide

Based on this trial design, predict the completion outcome and termination type (if applicable).